Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients.
The aim of this study was to analyze the concentration of anti-p53 antibodies in the serum of breast cancer patients and to correlate these results with various clinical, pathological and biochemical parameters. We also wanted to assess the prognostic significance of these antibodies in our patients. Sera from 61 patients with breast cancer and 20 individuals without malignancies were analyzed using enzyme-linked immunoadsorbent assay. High levels of anti-p53 antibodies were detected in twenty-one (35%) breast cancer patients and one control (5%). The difference was statistically significant. We observed an inverse relationship between the anti-p53 antibodies and the age of the patients. We found significant association of anti-p53 antibodies with tumor size, histological grade of the tumors and the number of axillary lymph nodes involved. The levels of anti-p53 antibodies were higher in patients with negative estrogen and progesterone receptors in comparison with patients with positive steroid receptors, but the difference was not statistically significant. No relation was observed between anti-p53 antibodies neither with the Cathepsin D levels in the cytosol nor with the HER-2/neu extracellular domain in the serum. Patients with primary tumors and higher levels of anti-p53 antibodies had shorter 5-year survival than patients with lower levels of anti-p53 antibodies. Our results support the role of anti-p53 antibodies as a biomarker of less favorable phenotype as well as a prognostic factor for patients with breast cancer.
Kulić
A
A
Department of Pathophysiology, University Hospital Center Zagreb, Kispatićeva 12, Zagreb, 10000, Croatia. ana.kulic1@zg.t-com.hr
Sirotković-Skerlev
M
M
Jelisavac-Cosić
S
S
Herceg
D
D
Kovac
Z
Z
Vrbanec
D
D
D000328:Adult; D000368:Aged; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D001324:Autoantigens / Q000276:immunology*; D001943:Breast Neoplasms / Q000097:blood / Q000276:immunology* / Q000401:mortality; D018270:Carcinoma, Ductal, Breast / Q000097:blood / Q000276:immunology* / Q000401:mortality / Q000556:secondary; D018275:Carcinoma, Lobular / Q000097:blood / Q000276:immunology* / Q000401:mortality / Q000556:secondary; D002402:Cathepsin D / Q000032:analysis; D002454:Cell Differentiation; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis / Q000276:immunology*; D010641:Phenotype; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000097:blood; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000276:immunology*
D001323:Autoantibodies; D001324:Autoantigens; D002402:Cathepsin D; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D016159:Tumor Suppressor Protein p53; C495901:TP53 protein, human; C508053:ERBB2 protein, human; C533922:CTSD protein, human